Category: Featured

Psychedelic IPOs build momentum as Atai Life Sciences goes public PITCHBOOK Making its Wall Street debut, Peter Thiel-backed Atai Life Sciences has become the third biotech...

View Post

Psychedelic Investor Conferences.

CONFERENCES Editor | Curator - July 13, 2021

Not Quite as Popular as the Bitcoin 2021 Conference Attended by 12,000 – But Worth Considering! Cowen Psychedelics & Novel Mechanisms...

View Post

Revive Therapeutics (RVV:CN, RVVTF) Approved to Trade on the OTCQB Market.

PSYCH STOCK NEWS Editor | Curator - June 25, 2021

TORONTO, June 25, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and development of...

View Post

Cybin (CYBN) Enters into Collaboration Agreement with Greenbrook TMS (GBNH) to Establish Mental Health Centers of Excellence.

PSYCH STOCK NEWS Editor | Curator - June 17, 2021

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has entered into an exclusive...

View Post

How Incannex is positioning to be the ‘next GW Pharma’, with CEO Joel Latham (Stockhead)

INTERVIEW Editor | Curator - April 28, 2021

Incannex provides investors the best of breed for medicinal cannabis and psychedelic therapy development – and they’re looking at an excursion to the USA For Incannex Healthcare (ASX:IHL) CEO...

View Post

Interview: Matt Stang, CEO of Delic (DELCF). Wall Street Reporter

CLINICS Editor | Curator - February 26, 2021

#delcf, #DELIC $delcf

View Post

1...101112 Page 11 of 12